| scholarly article | Q13442814 |
| P50 | author | Emir Hadzijusufovic | Q38327164 |
| Lukas Kenner | Q42434147 | ||
| Peter Valent | Q56697676 | ||
| Barbara Peter | Q56872611 | ||
| Harald Herrmann | Q56940149 | ||
| P2093 | author name string | M Willmann | |
| S Cerny-Reiterer | |||
| W F Pickl | |||
| V Yuzbasiyan-Gurkan | |||
| T Rülicke | |||
| T Thaiwong | |||
| K Schuch | |||
| P2860 | cites work | Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT | Q21142738 |
| Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumors | Q33238296 | ||
| Diagnostic criteria and classification of mastocytosis: a consensus proposal | Q33948617 | ||
| Mast cell tumors in the dog. | Q35173798 | ||
| Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. | Q35848377 | ||
| KIT mutations in mastocytosis and their potential as therapeutic targets | Q36576453 | ||
| Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria | Q36835061 | ||
| Mast cells and mastocytosis | Q36835143 | ||
| Generation and characterization of novel canine malignant mast cell line CL1. | Q37095268 | ||
| Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis | Q37247964 | ||
| Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy | Q37559690 | ||
| Tyrosine kinase inhibitors in veterinary medicine | Q37592418 | ||
| Gene expression analysis predicts insect venom anaphylaxis in indolent systemic mastocytosis. | Q38504083 | ||
| Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis | Q39615506 | ||
| In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V. | Q39692224 | ||
| Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells | Q39782974 | ||
| Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors | Q39958718 | ||
| Establishment of a novel high-affinity IgE receptor-positive canine mast cell line with wild-type c-kit receptors | Q40034438 | ||
| Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. | Q40048837 | ||
| Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells. | Q40097396 | ||
| Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells. | Q40188685 | ||
| Establishment and characterization of a new canine mast cell tumor cell line | Q40773689 | ||
| Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit | Q40959621 | ||
| Clustering of activating mutations in c-KIT's juxtamembrane coding region in canine mast cell neoplasms | Q40973424 | ||
| Establishment of an immature mast cell line from a patient with mast cell leukemia | Q41296878 | ||
| How much specific is the association between hymenoptera venom allergy and mastocytosis? | Q42457384 | ||
| Establishment of two dog mastocytoma cell lines in continuous culture | Q42810486 | ||
| Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors | Q42843077 | ||
| Detection of tryptase in cytoplasmic granules of basophils in patients with chronic myeloid leukemia and other myeloid neoplasms | Q43757354 | ||
| Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit | Q44539087 | ||
| Cladribine therapy for systemic mastocytosis. | Q44559230 | ||
| Kit and FcepsilonRI mediate unique and convergent signals for release of inflammatory mediators from human mast cells | Q44951894 | ||
| Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation. | Q45977986 | ||
| Masitinib is safe and effective for the treatment of canine mast cell tumors | Q46341707 | ||
| Gene expression profile, pathways, and transcriptional system regulation in indolent systemic mastocytosis. | Q46418767 | ||
| PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects | Q46724516 | ||
| Mast cell typing: demonstration of a distinct hematopoietic cell type and evidence for immunophenotypic relationship to mononuclear phagocytes. | Q50888369 | ||
| IgE-mediated anaphylaxis to Hippobosca equina in a patient with systemic mastocytosis. | Q52700313 | ||
| Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells. | Q54194510 | ||
| Response to interferon alfa-2b in a patient with systemic mastocytosis | Q67531413 | ||
| Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs | Q74815758 | ||
| P4510 | describes a project that uses | NI-1 | Q54930542 |
| P433 | issue | 7 | |
| P921 | main subject | mast cell | Q191989 |
| drug resistance | Q12147416 | ||
| cell line | Q21014462 | ||
| P304 | page(s) | 858-868 | |
| P577 | publication date | 2012-05-15 | |
| P1433 | published in | Allergy | Q2699825 |
| P1476 | title | NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation | |
| P478 | volume | 67 |
| Q57174064 | Comparative oncology: The paradigmatic example of canine and human mast cell neoplasms |
| Q48104415 | Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells. |
| Q91732120 | Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells |
| Q48120081 | IL-4 downregulates expression of the target receptor CD30 in neoplastic canine mast cells. |
| Q35114558 | Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA |
| Q99409940 | In vitro effects of histamine receptor 1 antagonists on proliferation and histamine release in canine neoplastic mast cells |
| Q39159911 | Oncostatin M is a FIP1L1/PDGFRA-dependent mediator of cytokine production in chronic eosinophilic leukemia |
| Q55362356 | Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy. |
| Q39189820 | Pharmacological targeting of allergen-specific T lymphocytes |
| Q48291629 | The JAK2/STAT5 signaling pathway as a potential therapeutic target in canine mastocytoma. |
| Q54930542 | NI-1 | described by source | P1343 |
Search more.